117 related articles for article (PubMed ID: 33112662)
1. Lamin B1 promotes tumor progression and metastasis in primary prostate cancer patients.
Luo F; Han J; Chen Y; Yang K; Zhang Z; Li J
Future Oncol; 2021 Feb; 17(6):663-673. PubMed ID: 33112662
[No Abstract] [Full Text] [Related]
2. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
3. ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancer.
Shimizu K; Matsumoto H; Hirata H; Ueno K; Samoto M; Mori J; Fujii N; Kawai Y; Inoue R; Yamamoto Y; Yano S; Shimabukuro T; Furutani-Seiki M; Matsuyama H
Oncol Rep; 2020 Dec; 44(6):2735-2745. PubMed ID: 33125156
[TBL] [Abstract][Full Text] [Related]
4. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
5. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.
Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY
Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616
[TBL] [Abstract][Full Text] [Related]
6. Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.
Bian Z; Huang X; Chen Y; Meng J; Feng X; Zhang M; Zhang L; Zhou J; Liang C
Int J Med Sci; 2021; 18(1):284-294. PubMed ID: 33390797
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
8. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
10. Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma.
Chen Y; Chen J; Shi Y; Ling X; Fang S; Zhong C; Liu F; Zhong W; Bi X; Dong Z; Lu J
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38224097
[TBL] [Abstract][Full Text] [Related]
11. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
12. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
[No Abstract] [Full Text] [Related]
13. Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.
Mo RJ; Lu JM; Wan YP; Hua W; Liang YX; Zhuo YJ; Kuang QW; Liu YL; He HC; Zhong WD
Curr Mol Med; 2017; 17(1):70-78. PubMed ID: 28231752
[TBL] [Abstract][Full Text] [Related]
14. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
Zhang M; Guan J; Huo YL; Song YS; Chen LZ
Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
[TBL] [Abstract][Full Text] [Related]
16. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
17. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.
Magi-Galluzzi C; Maddala T; Falzarano SM; Cherbavaz DB; Zhang N; Knezevic D; Febbo PG; Lee M; Lawrence HJ; Klein EA
Oncotarget; 2016 Jun; 7(23):33855-65. PubMed ID: 27121323
[TBL] [Abstract][Full Text] [Related]
18. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
20. Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma.
Yang Y; Gao L; Chen J; Xiao W; Liu R; Kan H
Bioengineered; 2022 Apr; 13(4):9211-9231. PubMed ID: 35436411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
